Testing pembrolizumab and lenvatinib for cancer that has spread to the brain
Original title: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, so it is not care your own doctor can give you.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests two drugs given together for tumors that have spread to the brain.
Who this trial is for. This trial is for people whose solid tumor has spread to the brain. It tests pembrolizumab and lenvatinib given together, including in breast cancer, lung cancer, and other solid tumors.
Where it stands. The trial is measuring whether tumors in the brain shrink. That answer is not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Someone whose cancer has spread to the brain may fit a trial like this. If that sounds like you, you can ask your care team about it. They can help you see if it makes sense for you.
What it doesn't mean: This does not mean these drugs work. A trial is a test, not proven treatment. Joining one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, October 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.